Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome

NCT00044304 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

70

Enrollment

NIH

Sponsor class

Conditions

Eosinophilic Myeloid Neoplasm
Hypereosinophilic Syndrome

Interventions

DRUG: Imatinib
DRUG: Ruxolitinib

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)